FREQ News and Press, Frequency Therapeutics Inc. From 03/10/23

2023-03-10 07:53:54 ET Frequency Therapeutics press release ( NASDAQ: FREQ ): Q4 GAAP EPS of -$0.49 beats by $0.14 . As of December 31, 2022, Frequency had cash, cash equivalents and marketable securities of $83.1 million (excluding restricted cash), or $68.9 million n...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022. ...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that interim Chief Executive Officer and Chief Scientific Officer Christopher Loose, Ph.D., will pres...

Frequency Therapeutics ( NASDAQ: FREQ ) is reducing its workforce by 55% and abandoning programs in Sensorineural Hearing Loss (SNHL) after FX-322 failed to meet the mail goal of a phase 2b study in people with acquired SNHL. Phase 2b trial : The company said the tri...

FX-322-208 Study Fails to Meet Primary Endpoint, Showing No Significant Separation in Speech Perception Between FX-322 and Placebo Company Will Now Focus on Advancing its Program in Remyelination for Multiple Sclerosis (MS) Announces Corporate Restructuring and Will Al...

VANCOUVER, BC / ACCESSWIRE / January 19, 2023 / Frequency Exchange Corp. ("Frequency Exchange" or the "Company") (TSXV:FREQ) is pleased to announce that its wholly-owned subsidiary, FREmedica Technologies Inc. ("FREmedica"), a technology based wellness company, has extended their relationship wi...

Global Neurology Leaders to Support Development of a Potentially Restorative Treatment for MS as Program Advances Toward 2023 Regulatory Filing Company also Expands Regenerative Medicine Advisory Board with Addition of Nobel Laureate and Cell Biologist Dr. James Rothman Frequenc...

Regenerative Treatment Designed to Increase Drug Exposure Through the Cochlea; Study Results Expected in H2 2023 Frequency’s Lead Hearing Program, FX-322, on Track for Phase 2b Topline Results in Q1 2023 Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regene...

December 13 Program to Review FX-322 Phase 2b Study and Endpoints, Physician Demand for Interventions to Treat Sensorineural Hearing Loss and Market Opportunity Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing ...

Frequency Therapeutics press release ( NASDAQ: FREQ ): Q3 GAAP EPS of -$0.55. Cash, cash equivalents and marketable securities as of September 30, 2022, were $99.3 million Based on current plans and assumptions, the Company believes its existing cash, cash equivalents ...